Aim: Insufficient ADAMTS13 activity (ADAMTS13:AC) leads to increased levels of unusually large von Willebrand factor (VWF) multimers and causes microcirculatory disturbance and multiple organ failure (MOF). Endotoxin (Et) triggers the activation of coagulation and cytokine cascades, leading to MOF in severe inflammatory response syndrome. Here, we investigated the potential role of endotoxemia-related ADAMTS13 in acute cholangitis.
INTRODUCTION
A DISINTEGRIN-LIKE AND metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) is a metalloproteinase that specifically cleaves multimeric von Willebrand factor (VWF), between residues Tyr1605 and Met1606, within the A2 domain.
1 ADAMTS13 is produced exclusively in hepatic stellate cells adjacent to endothelial cells (ECs), 2 while VWF is synthesized in vascular ECs and is released into plasma as unusually large VWF multimers (UL-VWFMs). 3 In cases of ADAMTS13 deficiency, released UL-VWFMs are improperly cleaved, leading to the accumulation of these proteins within the plasma. Notably, this accumulation can cause platelet clumping and thrombus formation under high shear stress, resulting in microcirculatory disturbances, and ultimately, to thrombotic thrombocytopenic purpura, 4 which is characterized by thrombocytopenia, renal dysfunction, fluctuating neurological symptoms, microangiopathic hemolytic anemia, and fever. 5 Previous studies reported that ADAMTS13 is involved in inflammation 6 and that ADAMTS13:AC decreases in patients with sepsis, 7 severe acute pancreatitis, 8 severe alcoholic hepatitis, 9 or disseminated intravascular coagulation (DIC), 7 suggesting that ADAMTS13 enzyme-VWF substrate imbalances are associated with progression of multiple organ failure (MOF), [7] [8] [9] and that the ratio of VWF antigen (VWF:Ag)/ADAMTS13 activity (ADAMTS13: AC) is linked to the severity of sepsis, pro-inflammatory cytokine levels, and MOF. 10 Furthermore, ADAMTS13 deficiency was found to be inversely correlated with platelet counts and directly correlated with cytokine and endotoxin (Et) levels in patients with severe acute pancreatitis and severe alcoholic hepatitis. 8, 9 These pathophysiologies were related to cytokines, whereas Et was associated with the development of DIC and/or MOF, which were impaired by blood coagulation-induced microcirculation. 8, 9 Endotoxins are present in the cell wall of gram-negative bacteria, and core lipid A is the toxic moiety of Et. Specifically, the term Et is typically used to indicate lipopolysaccharide. 11 Endotoxemia is thought to trigger the activation of coagulation and cytokine cascades, leading to MOF in severe inflammatory response syndrome. 11 Recently, an in vitro study reported that inflammatory cytokines are associated with decreased ADAMTS13:AC and increased release of UL-VWFM from ECs. 12 In addition, inflammation-associated ADAMTS13 deficiency was reported to promote UL-VWFM formation in patients with sepsis. 13 Together, these findings indicate a close link between ADAMTS13, cytokinemia, and endotoxemia.
The Et activity assay (EAA) comprises a novel and simple method for assessing blood levels of Et. Notably, this assay was reported to constitute a better diagnostic tool for sepsis than the kinetic turbidimetric Limulus test, which is widely used for detecting Ets.
14 The EAA might be particularly useful for the early identification of patients who are at high risk of developing severe sepsis and septic shock. 15 In the current study, we used this assay to investigate the relationship between endotoxemia and ADAMTS13:AC, and its related parameters, and attempted to determine whether imbalance of the enzyme-substrate ratio associated with endotoxemia contributes to the development of MOF through microcirculatory disturbances in patients with acute cholangitis.
METHODS

Patients
T WENTY-FOUR PATIENTS WITH acute cholangitis were enrolled in this study. All patients were originally admitted to our hospital between August and September 2010. Of them, 7 patients were diagnosed with severe acute cholangitis. The control group was comprised of 10 healthy volunteers, aged 20-40 years. Acute cholangitis was diagnosed based on criteria defined by TG13: Updated Tokyo Guidelines for the management of acute cholangitis and cholecystitis, according to physical findings, laboratory tests, and imaging diagnosis. 16 Twenty-two of the patients had undergone endoscopic retrograde biliary drainage. Disseminated intravascular coagulation was defined according to the revised diagnostic criteria proposed by the Japanese Ministry of Health, Labor, and Welfare. 17 Recently, these criteria have been widely used in Japan because they have higher sensitivity than those proposed by the International Society of Thrombosis and Haemostasis. 18 As such, by using the aforementioned criteria, we were able to diagnose DIC during the early stages. Two patients were diagnosed with DIC. All procedures involving human participants were undertaken in accordance with the ethical standards of the institutional, national research committee and with the 1964 Helsinki Declaration. This research project was approved by a suitably constituted Ethics Committee of the institution at which the work was undertaken.
Analyses of ADAMTS13:AC and VWF:Ag levels
Blood samples were obtained from patients at the time of admission or during their hospital stay, and were stored in plastic tubes containing a 0.38% volume (v:v) of sodium citrate. Platelet-poor plasma was prepared by centrifugation at 3000 g at 4°C for 15 min, and aliquots were stored at À80°C until analysis.
Plasma ADAMTS13:AC levels were determined using a sensitive chromogenic enzyme-linked immunosorbent assay (ELISA) (ADAMTS13-act-ELISA; Kainos Laboratories, Tokyo, Japan). The normal ADAMTS13-act-ELISA values were 99% ± 22%. Plasma VWF:Ag levels were measured using a rabbit polyclonal antibody sandwich ELISA (Dako, Glostrup, Denmark); normal levels were 100% ± 53%.
Cytokine analyses
Plasma levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-8 were determined using commercially available kits (Immunoassay Kits; BioSource International, Camarillo, CA, USA). The detection limits for plasma IL-6, TNF-α, and IL-8 were 7.8, 15.6, and 15.6 pg/mL, respectively.
Plasma Et analysis
Whole blood Et levels were measured using the commercially available EAA kit (Spectral Diagnostics, Toronto, Canada), which uses a luminol chemiluminescence method. Specifically, the EAA is based on the principle that Et binds to anti-Et antibodies and is delivered to ADAMTS13 and endotoxin in acute cholangitis E53 Hepatology Research 2018; 48: E52-E60 neutrophils by complement receptors. In the presence of β-glucan and luminol, neutrophils undergo a respiratory burst accompanied by light emission. The light produced is quantified using a chemiluminometer, and its intensity is proportional to the amount of Et present in the sample. 15 
Statistical analysis
Differences between the paired and unpaired groups were analyzed using the Mann-Whitney U-test, and correlations were calculated with Spearman's rank test. Categorical data were analyzed using the χ 2 -test (Fisher's exact test). Data were expressed as means ± standard deviation. A two-tailed P-value less than 0.05 was considered significant. All analyses were carried out using EZR (Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0, Vienna, Austria). Specifically, EZR is a modified version of R commander (version 1.6-3) that includes statistical functions frequently used in biostatistics. 19 
RESULTS
Clinical characteristics of patients with acute cholangitis
T HE CLINICAL CHARACTERISTICS of the patients included in this study are summarized in Table 1 . The study group comprised 12 men and 12 women, and the mean age of the patients with acute cholangitis was 69.9 ± 13.4 years. The mean white blood cell, C-reactive protein, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, γ-glutamyl transpeptidase, and serum total bilirubin levels of these patients were higher than the corresponding reference values. Conversely, the mean cholinesterase level was lower than the reference value, and the mean hemoglobin, platelet, prothrombin time, blood urea nitrogen, and serum creatinine levels were equal to the reference value. In total, 17 of the 24 patients showed mild to moderate cholangitis, while the remaining 7 showed severe acute disease. Notably, the patients with severe cholangitis showed higher prothrombin times and blood 
Plasma ADAMTS13:AC and VWF:Ag levels
The plasma ADAMTS13:AC levels of patients with acute cholangitis were significantly lower than those of healthy subjects (P < 0.05; Fig. 1 ). In contrast, the plasma VWF: Ag levels were significantly higher than those of healthy subjects (P < 0.05; Fig. 1 ). Likewise, the VWF:Ag/ ADAMTS13:AC ratios of patients with acute cholangitis were significantly higher than those of healthy subjects (P < 0.01; Fig. 1 ). In addition, plasma ADAMTS13:AC was directly correlated with platelet counts and inversely correlated with C-reactive protein levels (r = 0.47, P < 0.05 and r = À0.51, P < 0.05, respectively; Fig. 2 ). After recovery from cholangitis, patients showed increased plasma ADAMTS13:AC and decreased plasma VWF:Ag levels, similar to those of the healthy subjects.
Endotoxin activity assay levels and their relationship with ADAMTS13:AC
The EAA levels of patients with acute cholangitis were significantly lower than those of healthy subjects Figure 1 Clinical characteristics of patients with acute cholangitis. (a) ADAMTS13 activity levels of patients with acute cholangitis were significantly lower than that of healthy subjects (P < 0.05). (b) von Willebrand factor antigen (VWF:Ag) levels were significantly higher in patients with acute cholangitis than in healthy subjects (P < 0.05). (c) VWF/ADAMTS13 activity ratios of patients with acute cholangitis were markedly higher than those of healthy subjects (P < 0.05). (d-f) Serum levels of (d) interleukin (IL)-6, (e) IL-8, and (f) tumor necrosis factor-α (TNF-α) were significantly higher in patients with acute cholangitis than in healthy subjects (P < 0.05 for each). (P < 0.05; Fig. 3 ), and these levels were inversely correlated with ADAMTS13:AC (r = À0.41, P < 0.05; Fig. 3 ).
Plasma levels of cytokines and their relationship with ADAMTS13:AC and VWF:Ag levels
The IL-6, IL-8, and TNF-α (Fig. 1) plasma levels of patients with acute cholangitis were significantly higher than those of healthy subjects (P < 0.05 for all). Moreover, IL-6 levels were directly correlated with those of VWF:Ag (r = 0.55, P < 0.05; Fig. 2 ), and were inversely correlated with those of ADAMTS13:AC (r = À0.51, P < 0.05; Fig. 2 ). The levels of IL-8 (r = 0.26; Fig. 2 ) and TNF-α (r = 0.50; Fig. 2 ) were directly correlated with the VWF:Ag/ADAMTS13:AC ratio (P < 0.05 for both).
Relationship between ADAMTS13:AC and VWF:Ag levels among mild to moderate acute cholangitis and severe acute cholangitis patients, and with DIC scores
The plasma ADMTS13:AC levels of patients with severe acute cholangitis were significantly lower than those of patients with mild to moderate acute cholangitis (P < 0.05; Fig. 4a ). In contrast, the plasma VWF:Ag levels and the VWF:Ag/ADAMTS13:AC ratios of patients with severe acute cholangitis were significantly higher than Figure 5 Relationships between ADAMTS13 activity (ADAMTS13:AC), von Willebrand factor antigen (VWF:Ag) levels, and disseminated intravascular coagulation (DIC) scores in patients with acute cholangitis. (a) ADAMTS13:AC was inversely correlated with the DIC score (P < 0.05). (b) VWF:Ag was directly correlated with the DIC score (P < 0.05).
Figure 4
Relationship between ADAMTS13 activity (ADAMTS13:AC) and von Willebrand factor antigen (VWF:Ag) among patients with mild to moderate and severe acute cholangitis. ADAMTS13:AC was significantly lower (a), whereas VWF:Ag levels (b) and VWF/ ADAMTS13 activity ratios (c) were significantly higher in patients with severe acute cholangitis compared to those with mild to moderate acute cholangitis (P < 0.05 for each).
those of patients with mild to moderate disease (P < 0.05 for both; Fig. 4b,c) . Plasma ADMTS13:AC (r = À0.43; Fig. 5a ) and VWF:Ag (r = 0.51; Fig. 5b ) levels were inversely and directly correlated with the DIC score, respectively (P < 0.05 for both).
DISCUSSION W E PREVIOUSLY REPORTED that the plasma VWF: Ag levels increase and ADAMTS13:AC decreases in patients with severe acute pancreatitis 8 or severe alcoholic hepatitis. 9 In the current study, patients with acute cholangitis showed increased EAA, cytokine production, and VWF:Ag levels, but decreased ADAMTS13:AC. Moreover, EAA and cytokine levels, which are involved in DIC, were directly or inversely correlated with ADAMTS13:AC and the VWF:Ag levels. These results indicate that the decreased ADAMTS13:AC and the increased VWF:Ag levels observed in these patients might be closely associated with Et levels and cytokinemia in acute cholangitis; that is, ADAMTS13:AC and VWF:Ag levels are related to the pathophysiology of acute cholangitis.
Endotoxemia is known to play an important role in the initiation and aggravation of various diseases, including sepsis, 20 DIC, 20 and liver disease, 9,21-23 through increases in the levels of pro-inflammatory cytokines, including IL-6, IL-8, and TNF-α. In the current study, the IL-6, IL-8, and TNF-α levels were significantly higher in patients with acute cholangitis than in healthy subjects. A recent study reported that IL-6 inhibits the activity of ADAMTS13 under physiologic blood flow conditions and that IL-8 stimulates the dose-dependent release of UL-VWFMs from human umbilical vein ECs. 24 Intravenous infusion of Et to healthy volunteers was reported to decrease plasma ADAMTS13: AC and increase VWF:Ag levels, and to lead to UL-VWFM formation during acute systemic inflammation. 25 These findings indicate that enhanced endotoxemia might promote the observed decrease in ADAMTS13:AC through enhanced cytokinemia.
The plasma ADMTS13:AC of patients with severe acute cholangitis was lower and the plasma VWF:Ag levels and VWF:Ag/ADAMTS13:AC ratios were higher than those of healthy subjects. Recently, it was reported that marked imbalances involving decreased ADAMTS13:AC and increased VWF:Ag levels comprise an indicator for a high risk of sepsis with MOF. 10, 26 Notably, our results suggest that such imbalances are also involved in severe acute cholangitis. As ADAMTS13:AC is considerably reduced in patients with DIC, 20 ADAMTS13 deficiency might be associated with both severe acute cholangitis and DIC. Patients with DIC show hypercoagulability and a bleeding tendency. ADAMTS13 might therefore be pathophysiologically related to DIC. Indeed, we found that plasma ADAMTS13:AC was inversely correlated with the DIC score. Disseminated intravascular coagulation is associated with various disease states, including sepsis, which is the most common pathophysiological condition leading to the development of DIC. Indeed, 40% of patients with sepsis develop DIC. Endotoxemia and high circulating cytokine levels are thought to induce tissue factor expression, which in turn initiates platelet thrombus formation in circulating blood. 20, 27, 28 In our current study, the ADAMTS13:AC of patients with severe acute cholangitis was significantly lower than in those with mild to moderate illness. Combined with the fact that ADAMTS13:AC was also inversely correlated with DIC score, this finding indicates that ADAMTS13 activity could comprise an important marker for the diagnosis and prognosis of DIC, and that the pathophysiology of severe acute cholangitis might be closely related to DIC. Recently, it was reported that EAA is related to the severity of acute cholangitis. 29 Our study also found that such activity comprises a useful marker for assessment of acute cholangitis.
Endotoxemia is often treated using a polymyxin-B-immobilized fiber column-direct hemoperfusion (PMX-DHP) system, 30 which ameliorates sepsis-associated DIC. A PMX-DHP system aids in recovery of hemodynamics by endogenous cannabinoid adsorption and improves pulmonary oxygenation by indirect cytokine reduction through the adsorption of activated mononuclear cells. 30 However, PMX-DHP cannot directly treat hypercoagulability and bleeding tendency. Patients with sepsis-associated DIC undergo anticoagulant therapy and fresh-frozen plasma (FFP) infusion, which ameliorates the bleeding tendency in DIC associated with low ADAMTS13 levels, 7 and FFP has high ADAMTS13 levels. Recently, we reported that the use of FFP infusion as an ADAMTS13 replacement therapy also improves liver dysfunction, reflecting platelet hyperaggregability. 20 Fresh-frozen plasma infusion helps recover ADAMTS13:AC and may ameliorate severe acute cholangitis in DIC. Currently, recombinant ADAMTS13 is being developed, which could provide a new therapeutic option for DIC, including severe acute cholangitis, in the near future.
In conclusion, imbalance of ADAMTS13:AC and VWF: Ag levels might contribute to the development of severe acute cholangitis, reflecting platelet hyperaggregability. Severe acute cholangitis has severe pathophysiological features. Biliary drainage is a useful treatment option and decreases the death rate; however, some patients develop complications such as endotoxemia and MOF. Thus, it is becoming increasingly important to clarify the pathophysiology of this disease. To our knowledge, ours is the first study to report that ADAMTS13:AC and VWF:Ag levels are related to Et activity and cytokine levels in acute cholangitis. Based on these findings, we anticipate the development of new therapeutic approaches for treatment of this disease.
